Bile Acids and Portal Hypertension
Open Access
- 1 November 2017
- journal article
- review article
- Published by Elsevier in Annals of Hepatology
- Vol. 16 (Suppl. 1: ) , S83-S86
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular remodelling and sinusoidal dysfunctionJournal of Hepatology, 2017
- Beta adrenergic blockade and decompensated cirrhosisJournal of Hepatology, 2017
- Decoding the vasoregulatory activities of bile acid-activated receptors in systemic and portal circulation: role of gaseous mediatorsAmerican Journal of Physiology-Heart and Circulatory Physiology, 2017
- Emerging therapies for portal hypertension in cirrhosisExpert Opinion on Emerging Drugs, 2016
- Reversal of Endothelial Dysfunction by GPBAR1 Agonism in Portal Hypertension Involves a AKT/FOXOA1 Dependent Regulation of H2S Generation and Endothelin-1PLOS ONE, 2015
- Molecular pathophysiology of portal hypertensionHepatology, 2014
- Prevention of portal hypertension: From variceal development to clinical decompensationHepatology, 2014
- The changing role of beta-blocker therapy in patients with cirrhosisJournal of Hepatology, 2014
- On the in vitro vasoactivity of bile acidsBritish Journal of Pharmacology, 2000
- Bile acids as endogenous vasodilators?Biochemical Pharmacology, 1995